Scarica l'app Stockscreener
11.59
0.40%
0.0457
Mink Therapeutics Inc Borsa (INKT) Ultime notizie
MiNK Therapeutics | DEF 14A: Definitive information statements - Moomoo
Board elections and auditor vote at MiNK Therapeutics (NASDAQ: INKT) - Stock Titan
Director Holcomb of MiNK Therapeutics (NASDAQ: INKT) receives 4,174 stock options grant - Stock Titan
MiNK Therapeutics, Inc. (NASDAQ:INKT) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
Short Interest in MiNK Therapeutics, Inc. (NASDAQ:INKT) Drops By 30.6% - MarketBeat
Trading Systems Reacting to (INKT) Volatility - Stock Traders Daily
MiNK outlines initial ARDS phase II data in H2 2026 while extending runway through 2026 - MSN
MiNK Therapeutics (NASDAQ:INKT) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Buy Rating on MiNK Therapeutics Driven by Promising Phase 2 Survival Benefit and Immune Activation in PD-1–Refractory Gastric Cancer - TipRanks
INKT MiNK Therapeutics posts narrower Q4 2025 loss than expected, shares drop 9.78 percent on zero revenue. - Cổng thông tin điện tử Tỉnh Sơn La
MiNK Therapeutics (INKT) Stock Rights Issue (Weakens) 2026-04-22Professional Trade Ideas - UBND thành phố Hải Phòng
MiNK Therapeutics (INKT) Stock: Downside Risk (Crashes) 2026-04-20Real Time Stock Idea Network - Cổng thông tin điện tử tỉnh Lào Cai
Agenus cancer cocktail records 0% response rate, missing midstage goal - BioSpace
MiNK Therapeutics Reports Phase II Data on Immune Reprogramming and Durable Survival in PD-1 Refractory Gastroesophageal Cancer - Sahm
Melissa Orilall Net Worth (2026) - GuruFocus
In hard-to-treat gastroesophageal cancer, some patients lived 20+ months - Stock Titan
How Mink Therapeutics Inc. (INKT) Affects Rotational Strategy Timing - Stock Traders Daily
INKT SEC FilingsMink Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
The INKT Cell Story: Why Investors Need To Watch MiNK Therapeutics Closely - RTTNews
H.C. Wainwright Maintains MiNK Therapeutics(INKT.US) With Buy Rating, Maintains Target Price $35 - 富途牛牛
Retail Surge: What is MiNK Therapeutics Incs P E ratio telling us2026 Top Gainers & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Smart Money: Whats the fair value of MiNK Therapeutics Inc stockWeekly Stock Summary & AI Enhanced Trade Execution Alerts - baoquankhu1.vn
MiNK Therapeutics (INKT) finance officer reports 222 indirect shares on Form 3 - Stock Titan
Acute Respiratory Distress Syndrome Clinical Trial Pipeline Shows Potential with Active Contributions from 40+ Key Companies | DelveInsight - Dailyhunt
Fed Meeting: What is the target price for MiNK Therapeutics Inc stock2026 Key Highlights & Fast Entry High Yield Tips - baoquankhu1.vn
MiNK Therapeutics – Three Weeks. Three Catalysts - Oncodaily
INKT PE Ratio & Valuation, Is INKT Overvalued - Intellectia AI
Could a short squeeze happen in MiNK Therapeutics (INKT) Stock | INKT Q4 Earnings: Beats Estimates by $0.28Rating Downgrade - Cổng thông tin điện tử Tỉnh Sơn La
MiNK Therapeutics clarifies status of potential combination trials and investments By Investing.com - Investing.com
Will MiNK Therapeutics (INKT) Stock Hit Record Highs | Price at $11.96, Up 11.93%Bearish Pattern - Xã Thanh Hà
New Phase II Data on BOT/BAL Combination in Gastroesophageal Cancer at AACR 2026Agenus - Oncodaily
(INKT) and the Role of Price-Sensitive Allocations - Stock Traders Daily
MiNK Therapeutics, Inc. (NASDAQ:INKT) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
MiNK Therapeutics, Inc. (INKT) Stock Price, News, Quote & History - Yahoo! Finance Canada
MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study on agenT-797 with Checkpoint Inhibitors for PD-1 Refractory Gastroesophageal Cancer at AACR 2026 - geneonline.com
Agenus Announces Data from Phase II Study of BOT+BAL in Combinati - The National Law Review
MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026 - Investing News Network
HC Wainwright Issues Positive Outlook for INKT Earnings - MarketBeat
MiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of iNKT Cell Therapy - Sahm
MiNK AACR study targets gastroesophageal cancer after PD-1 failure - Stock Titan
MiNK Therapeutics' AgenT-797 Abstract Accepted for Presentation at ASGCT Annual Meeting 2026 - Quiver Quantitative
MiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of ... - Caledonian Record
MiNK Therapeutics’ (INKT) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society 2026 International Conference - Investing News Network
MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference - The Manila Times
MiNK Therapeutics Announces Abstract Acceptance for - GlobeNewswire
Mink Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView — Track All Markets
MiNK Therapeutics Reports Q4 and Full Year 2025 Results; Phase 2 Programs Advance with Impactful Non-Dilutive Momentum - Investing News Network
MiNK Therapeutics’ Earnings Call Signals High-Risk Upside - TipRanks
Earnings Call Summary | MiNK Therapeutics(INKT.US) Q4 2025 Earnings Conference - Moomoo
0.78%
3.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):